Artivion announces presentation of late-breaking clinical data at the 38th european association for cardio-thoracic surgery (eacts) annual meeting

5-year data from the amds darts trial demonstrates positive aortic remodeling with 94% of patients free from unanticipated reoperation 30-day data from the amds persevere trial shows cerebral malperfusion resolution in 90% of affected subjects post-amds implantation 1-year data from the neos study indicate e-vita open neo is safe and effective in the treatment of aortic arch pathologies with low combined major adverse events rate atlanta , oct. 10, 2024 /prnewswire/ -- artivion, inc. (nyse: aort), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its amds darts and persevere trials and e-vita open neo study presented in late-breaking science presentations at the 38th european association for cardio-thoracic surgery (eacts) annual meeting in lisbon, portugal. the presentation regarding the amds darts trial highlighted 5-year aortic remodeling data that demonstrate positive, durable patient outcomes following amds implantation.
AORT Ratings Summary
AORT Quant Ranking